Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
A minimalist illustration of a pill capsule representing drug development.

Jul 4, 2026

Anthropic wants to develop its own drugs

Anthropic is venturing into drug development with its new AI platform, Claude Science, aimed at enhancing scientific discovery.During the recent event “The Briefing: AI for Science,” Anthropic unveiled Claude Science, which integrates various scientific tools and datasets into a cohesive environment, enabling users to generate visuals and figures efficiently. The company emphasized the potential of AI to significantly expedite scientific advancements and healthcare solutions, boasting a range of
A minimalist illustration of a pill symbolizing drug discovery.

Jul 3, 2026

Insilico Medicine, Takeda Partner to Advance AI-Driven Drug Discovery

Insilico Medicine has formed a strategic partnership with Takeda to enhance drug discovery through artificial intelligence.In this collaboration, Insilico Medicine will spearhead the AI-driven discovery of new drug candidates utilizing its Pharma.AI platform, while Takeda will manage the clinical development and commercialization of selected candidates. The partnership aims to identify drug candidates that can stand out in Takeda's key therapeutic areas, focusing on improving both efficacy and s
A test tube with green liquid in a dimly lit lab

Jul 3, 2026

Hyderabad Startup Harnesses AI & Nanotechnology to Advance Autoimmune Skin Disorders & Wound Care

A Hyderabad-based startup, Acubiosys, is leveraging artificial intelligence and nanotechnology to develop innovative therapies for autoimmune skin disorders and wound care. By integrating these advanced technologies with biomedical research, the company aims to create targeted, effective treatments for chronic conditions.Acubiosys, incubated at the BRIC-CDFD Technology Incubator, employs AI algorithms to analyze extensive botanical databases and conducts three-dimensional molecular modeling to s
A close-up of a nanoparticle on a lab surface, symbolizing innovative psoriasis treatment.

Jul 3, 2026

Hyderabad-based startup harnesses AI to develop treatment for psoriasis

A Hyderabad-based startup, Acubiosys Private Limited, is leveraging artificial intelligence and nanotechnology to create innovative treatments for psoriasis and diabetic wounds.Founded within the BRIC-Centre for DNA Fingerprinting and Diagnostics incubator, Acubiosys focuses on developing evidence-based therapeutics for autoimmune conditions and skin disorders. Their approach combines AI-assisted drug discovery with nanotechnology, aiming to create safer, more targeted treatments for challenging
A minimalist representation of a drug compound molecule in flat design.

Jul 2, 2026

AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

Artificial intelligence (AI) is revolutionizing drug discovery, significantly reducing the time required for development and enhancing the potential for successful market entries.The traditional drug development process is notoriously lengthy, often spanning 10 to 15 years with a staggering 90% of candidates failing to gain approval. However, AI is transforming this landscape by optimizing drug discovery, allowing researchers to analyze millions of molecular combinations in weeks rather than yea
A minimalist illustration of a pill and capsule against a dark background.

Jul 2, 2026

AI-driven Drug Discovery Faces 2026 Test

The landscape of AI-driven drug discovery is poised for a significant evaluation in 2026, as a cohort of AI-generated drugs is set to enter critical Phase 3 trials.In a recent analysis by Michael Santoro, a business ethics professor, the implications of substantial investments in AI for drug discovery are scrutinized. Notable examples include Xaira’s ambitious $1 billion launch and Alphabet’s Isomorphic Labs, which secured $600 million in funding. Santoro references a Boston Consulting Group stu
A minimalist illustration of a pill bottle and an AI brain in flat design.

Jul 2, 2026

How Indian Pharma Firms Are Using AI to Cut Drug Discovery Time

Indian pharmaceutical companies are increasingly leveraging artificial intelligence (AI) to enhance drug discovery processes, aiming to cut down the traditionally lengthy and costly timeline associated with bringing new medications to market.The pharmaceutical sector faces significant challenges due to the lengthy and expensive nature of drug development, which often spans over a decade and costs billions. AI and machine learning technologies are now being employed to streamline this process, en
A glass vial and syringe in a dimly lit lab setting

Jul 2, 2026

Indian pharma uses AI to cut development time and costs

AI is revolutionizing the pharmaceutical landscape in India by significantly reducing the time and costs associated with drug development. Traditionally, the drug development process in India could span over a decade and incur substantial financial burdens. However, the integration of artificial intelligence and machine learning is transforming this paradigm. Rather than displacing the workforce, Indian pharmaceutical companies are leveraging AI as a collaborative tool to tackle complex scientif
A genomic sequence on paper in a collaborative workspace

Jul 2, 2026

Claude Hackathon Supercharges Life Sciences

Claude has launched the Built with Claude Life Sciences hackathon, aimed at advancing AI applications in the life sciences sector. In partnership with Gladstone Institute, this global virtual event offers a $100,000 prize pool for participants utilizing Claude's specialized tools for research and coding.The hackathon is designed to enhance the integration of AI in life sciences by providing participants with access to Claude Science and Claude Code. These tools facilitate the analysis of biologi
A petri dish with cultured cells in a dim laboratory setting, illuminated by soft ambient light.

Jul 2, 2026

Insilico Medicine and Takeda join to accelerate AI-powered drug discovery

Insilico Medicine has partnered with Takeda to enhance drug discovery through AI technologies, aiming to streamline the development of new therapies.This collaboration will leverage Insilico’s Pharma.AI platform alongside Takeda’s drug development expertise to expedite the identification and advancement of new drug candidates across key therapeutic areas. The partnership focuses on improving the efficiency of early-stage drug discovery while enhancing the probability of developing medicines with
A minimalist illustration of a pill and a light bulb representing AI drug discovery.

Jul 2, 2026

Takeda Invests $600M in Insilico's AI Drug Discovery

Takeda is making a significant move in the realm of AI-driven drug discovery by partnering with Insilico Medicine in a deal potentially worth up to $600 million. This collaboration will leverage Insilico's Pharma.AI platform to identify new drug candidates across Takeda's extensive therapeutic portfolio.The agreement allows Insilico to receive approximately $60 million in upfront and near-term payments, with additional success-based milestones potentially raising the total to $600 million. Taked
A scientist's hand holding a molecular compound in a dimly lit lab.

Jul 2, 2026

Mankind Pharma Partners with Denovo Sciences to Advance AI-Led Drug Discovery

Mankind Pharma has teamed up with Denovo Sciences to enhance drug discovery through artificial intelligence, aiming to streamline the R&D process.This collaboration merges Mankind Pharma's extensive research and clinical development expertise with Denovo Sciences' advanced AI platform, which specializes in molecular generation and prioritization. The partnership adopts a human-in-the-loop approach, allowing AI to generate and assess molecular candidates while scientists refine these candidates t